An observational national cohort study evaluating the safety and effectiveness of potent P2Y12 inhibitors ticagrelor and prasugrel compared to clopidogrel in East Asian patients with acute coronary syndromes
Latest Information Update: 01 Dec 2018
At a glance
- Drugs Clopidogrel (Primary) ; Prasugrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 01 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research